Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature

Cancer
William BlumClara D Bloomfield

Abstract

Acute myeloid leukemia (AML) with t(6;11)(q27;q23) is a well established but rare entity, and few studies have reported the full clinical, hematologic, and outcome data of patients with this disease. To characterize the features of t(6;11) AML, the authors searched the Cancer and Leukemia Group B (CALGB) cytogenetic database comprising 2667 adults with newly diagnosed, de novo AML and identified 16 patients (0.6%) with t(6;11). A review of the literature identified 33 adults with de novo t(6;11) AML for whom survival data were available. CALGB patients had a median age of 45 years (range, 22-65 years) and commonly presented with French-American-British (FAB) subtype M4 or M5 (81%). Gingival involvement at presentation was common (31%). All patients with gingival involvement had FAB M4. Compared with other patients with M4 AML in the CALGB database (n = 429), patients with M4 and t(6;11) (n = 7) had a higher frequency of gingival hypertrophy at presentation (71% vs. 17%, P = 0.003). Patients with t(6;11) were more likely to be African American (P = 0.02) and to die during induction (P = 0.03) than those without t(6;11). The complete response (CR) rate was 69% (11 of 16 patients), and CR duration was short (median, 9 months). The...Continue Reading

References

Jul 16, 1981·The New England Journal of Medicine·J J YunisK Ensrud
Jul 7, 1993·JAMA : the Journal of the American Medical Association·O RingdénM M Bortin
Aug 14, 1998·Journal of Pediatric Hematology/oncology·C A FelixB J Lange
May 18, 2001·Best Practice & Research. Clinical Haematology·K MrózekC D Bloomfield
Apr 17, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maria E Suarez-AlmazorEduardo Bruera
Jul 26, 2002·British Journal of Haematology·Alan K BurnettUNKNOWN Medical Research Council Adult and Paediatric Working Parties
Sep 18, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yves ChalandonDonna E Hogge
Dec 19, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·O RingdénF Frassoni
May 13, 2004·Genes, Chromosomes & Cancer·Attila FrigyesiMattias Höglund

❮ Previous
Next ❯

Citations

Jan 15, 2011·International Journal of Hematology·Chia-Chi ChengTuan-Jen Fang
Jul 14, 2012·International Journal of Hematology·Andrea Kühnl, David Grimwade
Nov 10, 2007·British Dental Journal·P Gallipoli, M Leach
May 14, 2011·Leukemia·B V BalgobindM M Van den Heuvel-Eibrink
Dec 3, 2010·Journal of Clinical and Experimental Hematopathology : JCEH·Hayato Tamai, Koiti Inokuchi
Jan 21, 2016·Expert Review of Hematology·Hsin-An Hou, Hwei-Fang Tien
Jun 14, 2015·American Journal of Clinical Pathology·Kathryn Foucar, John Anastasi
Aug 28, 2012·Journal of Clinical Pathology·Sai-Ching Jim YeungM James You
Feb 25, 2017·Frontiers in Pediatrics·Amanda C Winters, Kathrin M Bernt
Oct 7, 2020·Proceedings of the National Academy of Sciences of the United States of America·Marius BillClara D Bloomfield
Jun 3, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Clara D BloomfieldMichael A Caligiuri
Jun 3, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carolyn Compton
Nov 3, 2020·Journal of Pediatric Hematology/oncology·Graham D UnisRobert J Vasquez

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.